Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.
FAQs
BioNano Genomics Inc (BNGO) Stock Forecast, Price Targets and Analysts Predictions - TipRanks.com? ›
Average Price Target
What is the target price for BNGO? ›| High | $6.80 |
|---|---|
| Median | $6.00 |
| Low | $2.00 |
| Average | $4.93 |
| Current Price | $0.8896 |
According to our current BNGO stock forecast, the value of BioNano Genomics shares will rise by 13.71% and reach $ 0.917666 per share by June 22, 2024.
Does BioNano Genomics have a future? ›“We are pleased with our Q1 2024 results, which include significant growth in year-over-year revenue, expansion in the OGM system installed base, and advances to our end-to-end workflow,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.
Who are the largest investors in BNGO? ›Largest shareholders include Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Gsa Capital Partners Llp, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, BlackRock Inc., Citadel Advisors Llc, Susquehanna International Group, Llp, Jane Street ...
Is BNGO expected to rise? ›The average price target for BioNano Genomics Inc is $4.93. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $6.80 ,the lowest forecast is $2.00. The average price target represents 535.96% Increase from the current price of $0.775.
What is the BNGO forecast for 2025? ›According to analysts, BNGO price target is 4.93 USD with a max estimate of 6.80 USD and a min estimate of 2.00 USD.
Why is BNGO falling? ›What happened. A big change in the C-suite was behind the steep fall in Bionano Genomics' (NASDAQ: BNGO) share price on Monday. Following the biotech's announcement that its CFO is stepping down, investors traded out of the stock to the point where it closed the day more than 13% lower.
Does genomics have a future? ›“Genome sequencing will become the universal genetic test,” Ledbetter predicted. He suggested that, in the next 5 to 10 years, an individual's genome will be sequenced once, via a single test with a single CPT code, and then it will be reanalyzed as needed.
Is Bionano profitable? ›BioNano Genomics Inc's trailing 12-month revenue is $37.5 million with a -605.3% profit margin. Year-over-year quarterly sales growth most recently was 18.9%. Analysts expect adjusted earnings to reach $-1.737 per share for the current fiscal year. BioNano Genomics Inc does not currently pay a dividend.
Does BlackRock own BNGO? ›
2023-07-07 - BlackRock Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,136,883 shares of Bionano Genomics, Inc. (US:BNGO). This represents 2.0 percent ownership of the company.
How much cash does BNGO have? ›| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $0.11 B | -54.84% |
| 2021-12-31 | $0.25 B | 551.8% |
| 2020-12-31 | $38.44 M | 122.1% |
| 2019-12-31 | $17.31 M | 4.77% |
The ownership structure of BioNano Genomics (BNGO) stock is a mix of institutional, retail and individual investors. Approximately 6.66% of the company's stock is owned by Institutional Investors, 8.78% is owned by Insiders and 84.56% is owned by Public Companies and Individual Investors.
What is the target price prediction? ›TGT Stock 12 Month Forecast
Based on 28 Wall Street analysts offering 12 month price targets for Target in the last 3 months. The average price target is $179.81 with a high forecast of $210.00 and a low forecast of $116.00. The average price target represents a 26.15% change from the last price of $142.54.
The main competitors of Bionano Genomics include Harvard Bioscience (HBIO), Seer (SEER), Akoya Biosciences (AKYA), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), Singular Genomics Systems (OMIC), Talis Biomedical (TLIS), Astrotech (ASTC), and Precipio (PRPO).
How much cash does bngo have? ›| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $0.11 B | -54.84% |
| 2021-12-31 | $0.25 B | 551.8% |
| 2020-12-31 | $38.44 M | 122.1% |
| 2019-12-31 | $17.31 M | 4.77% |
SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.